TRDX Trend Exploration Inc (PK)

SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) today announces it has executed a binding Letter of Intent with Montreal-based Genesis Bio Pharma, Inc. to acquire an exclusive worldwide sublicense for a new compound in development for the treatment of Painful Diabetic Neuropathy (PDN).

PDN is one of many complications of diabetes. Forty to fifty percent of diabetic patients may develop PDN over 15 to 20 years. PDN is present in 11.6% of patients with Type I diabetes and 32.1% of patients with Type II diabetes. PDN may present itself as a progressive build-up of unpleasant sensory symptoms including tingling (paraesthesia), burning pain, shooting pain down the legs and toes and lancinating or contact pain. The pain is more severe during the night and often prevents sleep. Some patients may be in a constant state of tiredness because of sleep deprivation while others are unable to maintain employment.

Dr. Jan Stahl CEO, of TRDX, commented: "We are ecstatic to reach this binding Letter of Intent stage with Genesis. Their work in the treatment of diabetic neuropathy is groundbreaking and we look forward to being a major part in bringing this innovation to the world. We will work diligently to complete the definitive agreement and closing as soon as possible."

Dr. Leo Stella, CEO of GENESIS Bio Pharma, stated: "Our mission is aimed at the development of proprietary drugs for the treatment of complications of diabetes, specifically, PDN. We received approval from the Therapeutic Product Directorate (TPD) of Health Canada to initiate Phase I clinical trials with our lead compound R-954. Our alliance with TRDX will help us accomplish our aim by initiating the clinical trials as soon as possible."

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company's business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

Contact: SciMeDent Health Corp. f/k/a Trend Exploration, Inc. dmyers@cadenceconsultingllc.com 1-866-383-1374